Crossmark

A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats

Crossref DOI link: https://doi.org/10.1186/s12917-019-1893-x

Published Online: 2019-05-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lopes, Natália Lôres https://orcid.org/0000-0003-4659-5815
Campos, Diefrey Ribeiro

Machado, Marília Alves

Alves, Mariana Silva Revoredo

de Souza, Manuela Silva Gomes

da Veiga, Cristiano Chaves Pessoa

Merlo, Alexandre

Scott, Fábio Barbour

Fernandes, Julio Israel
Funding

Funding for this research was provided by:

Zoetis (doanted oclacitinib tablets)

CAPES (Finance code 001)
License Information

Text and Data Mining valid from 2019-05-08
More Information

Article History

Received: 12 December 2018

Accepted: 29 April 2019

First Online: 8 May 2019

Ethics approval

: This study was submitted and approved by the Veterinary Institute Ethics Committee (CEUA/IV) (number 4534191017).

: Not applicable.

: The oclacitinib tablets were donated by Zoetis.Alexandre Merlo is a current employee of Zoetis in Brazil.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.